Alternative Data for Clene
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 425 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 19 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,179 | Sign up | Sign up | Sign up |
| X Followers | 850 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $7,000 | Sign up | Sign up | Sign up |
| Linkedin Employees | 69 | Sign up | Sign up | Sign up |
About Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
| Price | $5.19 |
| Target Price | Sign up |
| Volume | 66,850 |
| Market Cap | $63M |
| Year Range | $2.37 - $12.5 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
Accurate quantification of steps from multiple smartphone positionsJanuary 6 - Nature.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 15,000 | 0 | 15,000 | -8.8M | -7.8M | -0.608 |
| Q2 '25 | 27,000 | 370,000 | 27,000 | -7.4M | -6.4M | -0.780 |
| Q1 '25 | 81,000 | 20,000 | 61,000 | -750,000 | 260,000 | -0.500 |
| Q4 '24 | 91,000 | 18,000 | 73,000 | -14M | -13M | -1.365 |
| Q3 '24 | 87,000 | 18,000 | 69,000 | -8M | -6.6M | -1.107 |
Insider Transactions View All
| Ugwumba Chidozie filed to sell 599,603 shares at $5.3. January 23 '26 |
| Ugwumba Chidozie filed to sell 605,159 shares at $5.3. January 23 '26 |
| Ugwumba Chidozie filed to sell 617,824 shares at $5.1. January 21 '26 |
| Ugwumba Chidozie filed to sell 629,943 shares at $4.8. January 21 '26 |
| Ugwumba Chidozie filed to sell 642,375 shares at $5.1. January 21 '26 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$224.44 1.3% | 44 |
 |
Eli Lilly and CompanyLLY |
$1039.51 2.2% | 62 |
 |
PfizerPFE |
$26.5 2.4% | 51 |
 |
AstrazenecaAZN |
$95.6 1.5% | 49 |
 |
AbbVieABBV |
$223.93 1.4% | 53 |
Read more about Clene (CLNN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, lobbying cost & linkedin employees.
FAQ - Clene
The Market Cap of Clene is $63M.
Currently, the price of one share of Clene stock is $5.19.
The CLNN stock price chart above provides a comprehensive visual representation of Clene's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Clene shares. Our platform offers an up-to-date CLNN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Clene (CLNN) does not offer dividends to its shareholders. Investors interested in Clene should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Clene are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
